Enanta Pharmaceuticals ENTA
NASDAQ ENTA
$14.08 +0.06 (+0.43%)
As of: Sep 4, 2026 · 3:59 PM EDT

Enanta Pharmaceuticals (ENTA) Revenue Growth (3y) (2015 - 2026)

Analysis

Enanta Pharmaceuticals (ENTA) Revenue Growth (3y) (2015 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 10.17%
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 10.76%
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 77.85%
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -25.02%
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 42.02%
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 59.40%
8 Royalty Pharma 28.45 Bn 27.61 Bn - 7.80%
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 76.62%
10 Enanta Pharmaceuticals 409.30 Mn 219.79 Mn - -8.74%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -8.74%
Mar 31, 2026 -1.21%
Dec 31, 2025 -7.59%
Sep 30, 2025 -9.37%
Jun 30, 2025 -2.03%
Mar 31, 2025 -7.27%
Dec 31, 2024 -15.03%
Sep 30, 2024 -14.75%
Jun 30, 2024 -5.98%
Mar 31, 2024 -5.38%
Dec 31, 2023 -17.23%
Sep 30, 2023 -7.12%
Jun 30, 2023 0.43%
Mar 31, 2023 -13.63%
Dec 31, 2022 -23.45%
Sep 30, 2022 -26.57%
Jun 30, 2022 -24.00%
Mar 31, 2022 -22.13%
Dec 31, 2021 -26.59%
Sep 30, 2021 -29.47%